`BIB_379`

Antihypertensive medications and melanoma risk + RAAS inhibitors during ICI — evidence synthesis 2023–2024: Cohen 2024 JID Innov meta-analysis (42 studies; ACE inhibitors → melanoma RR 1.09, 95% CI 1.03–1.14; quality LOW/VERY LOW; dose-response signal for ACEi + thiazides + melanoma); Ghiasvand 2023 Int J Epidemiol nationwide nested case-control Norway (n≈3.9M; antihypertensives → melanoma signal "not strong enough to indicate UV-sensitisation mechanism" after residential UV adjustment); IARC Monographs Vol 137 Nov 2024 (hydrochlorothiazide Group 1 carcinogen for skin SCC + lip — patient is on…

Evidence grade: B
Tier: 2 (Cohen 2024 JID Innov — systematic review + meta-analysis 42 studies;
Cited by tasks: 13a, 18, 24
Identifiers: PMC11087973 · DOI:10.1016/j

↗ Follow the original source for full context

Full extracted findings & patient-implication analysis: bibliography/BIB_379/findings.md (research corpus). This page is a short context summary — not individualised medical advice.